Comparing the current results to its competitors, Engene Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 155.07 %, recorded in the same quarter.
July 8, 2025
enGene Holdings Inc.: Strategic Leadership Appointments and Financial Progress in Non-Viral Gene-Based Immunotherapy enGene Holdings Inc., a Boston and Montreal-based clinical-stage company specializing in non-viral gene-based immunotherapy, has made significant strides in its strategic positioning, governance, and financial outcomes. This article discusses the recent board appointments intended to bolster commercial readiness, insights from the latest financial results, and updates on clinical trial progress, highlighting the company s trajectory toward innovative treatments in therapeutic areas such as oncology. The pharmaceutical landscape is evolving rapidly, particularly in the realm of gene therapie...
April 4, 2025
In a recent announcement under NASDAQ Listing Rule 5635(c)(4), Engene Holdings Inc has disclosed a strategic management of its liabilities, leading to notable advancements in its financial health for the first quarter of 2024. The company reported a commendable decrease of 6.74% in repayments of liabilities, contributing to an enhanced leverage ratio of 0.14, which surpasses Engene s typical average.The impact of this achievement is significant, especially when contextualized within the broader industry landscape. Engene Holdings Inc now ranks favorably against 19 other companies within the biopharmaceutical sector, all of which reported lower leverage ratios during the same period. This upward movement posi...
December 20, 2024
enGene Reports Full Year 2024 Financial Results and Business Update Amid Promising Developments in Cancer Therapy BOSTON and MONTREAL enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company known for its innovative non-viral investigational product, detalimogene voraplasmid, has announced its financial results for the full year ending 2024, alongside crucial updates regarding its pivotal study in patients suffering from high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).As enGene advances its lead product, detalimogene voraplasmid, currently undergoing essential clinical trials, the company also reported ...
September 10, 2024
An Update from the Realm of Genetic Medicine: enGene Reports Third Quarter Financials Amidst a Pivotal Clinical Journey In the year of our Lord, two thousand and twenty-four, enGene Holdings Inc. a distinguished enterprise in the arena of genetic therapeutics, has unveiled its financial tableau for the third quarter. Operating from the storied cities of Boston and Montreal, this clinical-stage company stands at the forefront of an unparalleled medical endeavor, as it champions the cause of its leading investigational product, the notable detalimogene voraplasmid, once known in the annals of research as EG-70.Verily, enGene hath embarked upon an ambitious quest, thrusting itself into the fray against the most...
Urogen Pharma Ltd is a pharmaceutical company that specializes in developing and commercializing innovative therapies for urological and oncological conditions. Their business model revolves around conducting extensive research and development to create novel therapies, obtaining necessary regulatory approvals, and strategically partnering with healthcare providers and other stakeholders to market and distribute their products globally. By focusing on addressing unmet medical needs in the urology field, Urogen Pharma aims to improve patient outcomes and establish a strong presence in the market.
Sources:
Engene Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Engene Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
